A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients with Presbyopia

Project: Other project

StatusFinished
Effective start/end date9/21/169/20/18

Funding

  • Allergan: $6,538.46